Dashboard
1
Poor Management Efficiency with a low ROCE of 0.13%
- The company has been able to generate a Return on Capital Employed (avg) of 0.13% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 30.90% and Operating profit at 14.27% over the last 5 years
4
Flat results in Jun 26
5
With ROE of 4.13%, it has a expensive valuation with a 8.45 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 20,249 Million (Large Cap)
205.00
NA
0.00%
0.25
4.13%
5.46
Revenue and Profits:
Net Sales:
713 Million
(Quarterly Results - Jun 2026)
Net Profit:
20 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-43.38%
0%
-43.38%
6 Months
25.58%
0%
25.58%
1 Year
42.62%
0%
42.62%
2 Years
225.54%
0%
225.54%
3 Years
116.25%
0%
116.25%
4 Years
139.6%
0%
139.6%
5 Years
152.74%
0%
152.74%
Zhejiang Hengtong Holding Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
30.90%
EBIT Growth (5y)
14.27%
EBIT to Interest (avg)
-28.51
Debt to EBITDA (avg)
3.04
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.32
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.13%
ROE (avg)
7.93%
Valuation key factors
Factor
Value
P/E Ratio
205
Industry P/E
Price to Book Value
8.45
EV to EBIT
-861.68
EV to EBITDA
525.22
EV to Capital Employed
6.95
EV to Sales
14.90
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.81%
ROE (Latest)
4.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
713.40
696.60
2.41%
Operating Profit (PBDIT) excl Other Income
46.60
23.60
97.46%
Interest
8.40
9.10
-7.69%
Exceptional Items
-64.80
14.90
-534.90%
Consolidate Net Profit
19.80
71.80
-72.42%
Operating Profit Margin (Excl OI)
15.80%
-16.80%
3.26%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 2.41% vs 18.47% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -72.42% vs 483.74% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,849.80
1,325.90
39.51%
Operating Profit (PBDIT) excl Other Income
101.60
88.60
14.67%
Interest
22.20
23.20
-4.31%
Exceptional Items
34.30
-23.90
243.51%
Consolidate Net Profit
200.90
165.60
21.32%
Operating Profit Margin (Excl OI)
-14.00%
-13.00%
-0.10%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 39.51% vs 105.22% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 21.32% vs 8.09% in Dec 2024
About Zhejiang Hengtong Holding Co., Ltd. 
Zhejiang Hengtong Holding Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






